Business Wire

MA-EXAGRID

15.9.2020 14:02:11 CEST | Business Wire | Press release

Share
ExaGrid Announces New Software Version 6.0

ExaGrid®, the industry’s only Tiered Backup Storage solution, today announced the release of software Version 6.0, which begins shipping on September 18, 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200915005278/en/

Key features include:

New Retention Time-Lock for Ransomware Recovery

Retention Time-Lock is a revolutionary approach to protecting backup retention data to enable fast and easy recovery from ransomware.

  • ExaGrid’s two-tier architecture includes a network-facing tier and a non-network-facing tier. ExaGrid alone controls the non-network-facing tier, creating a tiered air gap.
  • Backups are written to the network-facing-tier for fast backup performance. The most recent backups are kept in their full undeduplicated form for fast restores.
  • Data is adaptively deduplicated (for storage cost efficiency) into the non-network-facing tier for long-term retention data. Organizations can have as many days, weeks, months, or years of retention as they require. There is no limit to the number of version retention copies that can be saved.
  • In addition to the long-term retention, ExaGrid offers a policy-driven approach allowing for any delete requests issued to the network-facing tier to be delayed in the non-network-facing tier for a specified number of days, so that backup data will not be deleted when a hacker takes control of the backup application or backup storage.
  • If encrypted data is sent to the network-facing tier, or if any of its data is encrypted, ExaGrid’s repository is protected as all the deduplication objects are immutable because they are never modified.

ExaGrid assumes the hackers will take control of the backup application or the backup storage and will issue delete commands for all backups. ExaGrid has the only non-network-facing tiered backup storage solution (a tiered air gap) with delayed deletes and immutable deduplication objects. This unique approach ensures when a ransomware attack occurs, data can be easily recovered or VMs booted from the ExaGrid Tiered Backup Storage system. Not only can the primary storage be restored, but all retained backups remain intact.

“ExaGrid’s Version 6.0 provides our customers with a new strategy for ransomware recovery: ExaGrid’s Retention Time-Lock, which prevents hackers from deleting data stored in our system’s repository tier as all deletes are delayed by a policy setting. This unique approach allows customers to recover data in the event that the primary storage has become compromised by ransomware or malware,” said Bill Andrews, ExaGrid’s President and CEO. “Unlike other approaches, which require the purchase of an additional storage unit, our approach only requires that customers allocate 2% to 10% of additional repository storage in their existing system with an adjustable delay period, which is in line with our goal of offering the most cost-effective solutions to our customers.”

Security Enhancements (in addition to Ransomware Recovery), New UI Platform, and Other Highlights of Version 6.0

Version 6.0 includes the following security enhancements:

  • New security officer role governs any changes to the Retention Time-Lock policy
  • Optional Two-Factor authentication in web-based user interface using any OAUTH-TOTP app
  • Additional control over SSH access
  • Utilize Active Directory credentials from trusted domains to control share and user interface access
  • New operator role for day to day operations reduces the need for administrator access.
  • Security checklist for quick and easy implementation of best practices
  • Automatic user interface logout after a period of inactivity

Version 6.0 includes the following additional features:

  • User interface improvements provide intuitive details about how the ExaGrid system’s storage capacity is being utilized
  • Streamlined navigation experience
  • Deduplication and replication performance improvements across multiple backup applications

ExaGrid’s Unique Approach: Tiered Backup Storage

Disk-cache Landing Zone (Performance Tier)

  • ExaGrid writes directly to disk for the fastest backup performance
  • ExaGrid restores directly from disk for the fastest restores and VM boots

Long-term Retention Repository (Retention Tier)

  • ExaGrid tiers long-term retention to a deduplicated data repository to reduce storage and resulting storage costs

Backing up to low-cost disk is fast for backups and restores, however, with longer-term retention, the amount of disk required becomes extremely expensive.

To reduce the amount of disk for long-term retention, deduplication appliances reduce the amount of storage and cost, however the deduplication is performed inline on the way to the disk which slows down backups to about one-third the performance of disk. Also, the data is only stored in deduplicated format resulting in extremely slow restores and VM boots as the data has to be reassembled, or rehydrated, for each request. In addition, deduplication appliances are scale-up storage which only adds storage capacity as data grows, resulting in backup windows that continue to grow as data grows, expensive forklift upgrades, and forced product obsolescence.

ExaGrid Tiered Backup Storage writes directly to disk for the fastest backups, and restores directly from disk for the fastest restores and VM boots. ExaGrid then tiers the long-term retention data to a deduplicated data repository to reduce the amount of retention storage and resulting cost. In addition, ExaGrid provides a scale-out architecture where appliances are simply added as data grows. Each appliance includes processor, memory, and network ports, so as data grows, all resources required are available to maintain a fixed-length backup window. This scale-out storage approach eliminates expensive forklift upgrades, and allows for mixing appliances of different sizes and models in the same scale-out system which eliminates product obsolescence while protecting IT investments up front and over time.

ExaGrid offers the best of both worlds by offering low-cost disk for the fastest backup and restore performance tiered to a deduplicated data repository for the lowest cost retention storage. The scale-out storage architecture provides a fixed-length backup window and is low cost up front and over time.

About ExaGrid

ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. Visit us at exagrid.com or connect with us on LinkedIn . See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our success stories .

ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye